e u.s. food and drug administration today approved yescarta ( axicabtagene ciloleucel ) , a cell-based gene therapy , to treat adult patients with certain types of large b-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment . newline_char yescarta , a chimeric antigen receptor ( car ) t cell therapy , is the second gene therapy approved by the fda and the first for certain types of non-hodgkin lymphoma ( nhl ) . newline_char in just several decades , gene therapy has gone from being a promising concept to a practical solution to deadly and largely untreatable forms of cancer , ” said fda commissioner scott gottlieb , m.d . newline_char “ today marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases . newline_char that policy will also clarify how we will apply our expedited programs to breakthrough products that use car-t cells and other gene therapies . newline_char “ this approval demonstrates the continued momentum of this promising new area of medicine and we ’ re committed to supporting and helping expedite the development of these products . story_separator_special_tag fda commissioner scott gottlieb , himself a cancer survivor , called yescarta " another milestone in the development of newline_char but the treatment feldman received was just approved by the food and drug administration under the brand name yescarta , with a bracing price tag : $ 373,000 per patient . newline_char that does n't include the costs of dealing yescarta 's side effects , which include life-threatening fevers triggered by the immune response the therapy creates that can mean weeks in the hospital , or other drugs patients must receive . newline_char that 's still a long way away . newline_char what actually worked for the 55-year-old photographer was a radical treatment in which his own white blood cells were genetically re-engineered to kill his cancer .
